More positive data for semaglutide in weight loss

24 March 2021

New results from the STEP Phase IIIa clinical trial program demonstrated weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4mg versus placebo.

In the STEP 4 trial, study participants who reached the maintenance dose of semaglutide 2.4mg during a 20-week run-in period were randomized to either continue treatment with semaglutide 2.4mg or switch to placebo for 48 weeks.

The full results of the STEP 4 trial were presented Tuesday by Danish diabetes care giant Novo Nordisk (NOV: N) at the virtual Endocrine Society (ENDO) 2021 Annual Meeting and published in the Journal of the American Medical Association.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK